AbbVie, Enanta post stellar hep C PhIII data, but no one is cheering
First, the good news about new Phase III data from AbbVie $ABBV and its partner Enanta $ENTA on their hep C combo for glecaprevir/pibrentasvir.
The data were absolutely stellar. Fully 99% of genotype 1, 2, 4, 5 or 6 patients — in 145 of 146 patients — saw their virus disappear after 12 weeks of treatment. They did that without ribavirin and without turning away a likely group of resistant patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.